Business News • PR NewsWire • PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

MADRID and DUBLIN, Jan. 22, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended "HSR", with respect to the exclusive license agreement for...

View More : https://www.prnewswire.com:443/news-releases/pharmamar-and-jazz-pharmaceuticals-announce-the-us-license-agreement-for-lu...

Releted News by prnewswire

Společnost ToJoy přispěje částkou 100 milionů juanů na pomoc zakořenění myšlenky Velkého sdílení

U.S. News Special Report: Stockton, Calif., Is the Most Diverse City in America

Unlocking Investment to Scale Innovation in Fashion

PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015

Hansa Biopharma to Host Conference Call to Provide Year-End report 2019 and Business Update

TTEC announces new contract win with Volkswagen Group UK and opens a new contact centre in Leeds